In a report released today, Lawrence Keusch from Raymond James initiated coverage with a Buy rating on Avantor (AVTR). The company’s shares closed last Monday at $26.82, close to its 52-week high of $27.02.
According to TipRanks.com, Keusch is a 4-star analyst with an average return of 5.4% and a 59.7% success rate. Keusch covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Intuitive Surgical.
Currently, the analyst consensus on Avantor is a Strong Buy with an average price target of $27.86, representing a 0.3% upside. In a report issued on October 28, Wells Fargo also maintained a Buy rating on the stock with a $28.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.02 and a one-year low of $6.66. Currently, Avantor has an average volume of 5.65M.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AVTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
